Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Somatuline generic name?
Drugpatentwatch market analysis industry today?
Alogliptin benz cost?
Mebendazole 100mg price?
Brenzavvy discontinuation?

What are key competitors to nucala?

See the DrugPatentWatch profile for nucala

Nucala (mepolizumab) is an anti‑IL‑5 monoclonal antibody approved for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. Its main competition comes from other biologics that also target the type‑2 inflammatory axis or eosinophils:

Competitor Drug name Target Key Indications Notable Points
Benralizumab Fasenra IL‑5 receptor α (depletes eosinophils via antibody‑dependent cell‑mediated cytotoxicity) Severe eosinophilic asthma One‑dose per month (or bi‑monthly) SC; rapid eosinophil depletion
Reslizumab Cinqair IL‑5 Severe eosinophilic asthma IV infusion (weekly or bi‑weekly)
Omalizumab Xolair IgE Allergic asthma (and chronic spontaneous urticaria) Monthly SC; broader IgE‑mediated disease coverage
Dupilumab Dupixent IL‑4 receptor α (blocks IL‑4/IL‑13 signaling) Severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis Monthly SC; dual cytokine blockade
Tralokinumab Tezspire (US) IL‑13 Moderate‑to‑severe atopic dermatitis (not asthma) Still investigational for asthma; not a direct competitor yet
Lebrikizumab Lebrikizumab (investigational) IL‑13 Severe asthma (clinical trials) Still in development; potential future competitor

How they stack up

Feature Nucala (mepolizumab) Fasenra (benralizumab) Cinqair (reslizumab) Xolair (omalizumab) Dupixent (dupilumab)
Mechanism IL‑5 blockade → reduced eosinophil survival IL‑5Rα blockade → eosinophil depletion IL‑5 blockade IgE neutralization IL‑4/IL‑13 blockade
Route SC once every 4 weeks SC every 4 weeks (or 8 weeks) IV every 4 weeks SC monthly SC every 2 weeks (or 4 weeks)
Key efficacy data ↓ exacerbations, ↓ OCS use ↓ exacerbations, ↓ OCS use ↓ exacerbations, ↓ OCS use ↓ exacerbations (allergic phenotype) ↓ exacerbations, improved lung function
Safety profile Injection site reactions, rare hypersensitivity Similar to Nucala; eosinophil‑related Similar to Nucala Injection site, anaphylaxis risk Injection site, conjunctivitis, rare infections
Cost considerations Typically ~$12–15k/yr (US) ~$15–18k/yr ~$12–15k/yr ~$10–12k/yr ~$22–24k/yr

Take‑away

  • Benralizumab and Reslizumab are the most direct competitors because they target the same upstream cytokine (IL‑5) but differ in administration and mechanism.
  • Dupilumab is a broader type‑2 cytokine blocker and has shown comparable efficacy in many patients, especially those with comorbid chronic rhinosinusitis or atopic dermatitis.
  • Omalizumab remains important for patients with allergic asthma where IgE plays a central role.
  • Emerging IL‑13 inhibitors (e.g., Tralokinumab, Lebrikizumab) could become competitors as clinical data mature.

When choosing therapy, clinicians weigh factors such as disease phenotype (eosinophilic vs. allergic), prior exacerbation history, comorbidities, route of administration, and insurance coverage.



Other Questions About Nucala :

nucala biosimilar Biosimilars for nucala? How does nucala differ from xolair? Nucala equivalent? Nucala and xolair? Who makes nucala? Nucala off patent?